PURPOSE: Response to front-line treatment and subsequent clinical course for patients with chronic lymphocytic leukemia (CLL) are heterogeneous. Identifying pretreatment patient characteristics or prognostic factors associated with clinical outcomes is important for counseling patients, conducting clinical research, and evaluating trial results. PATIENTS AND METHODS: We evaluated the pretreatment characteristics of 595 previously untreated patients who had National Cancer Institute Working Group indications to initiate front-line therapy for predictors of complete response (CR), time to treatment failure (TTF), and overall survival (OS). Multivariable models were developed for all three end points. RESULTS: CR is an important treatment end point correlated with longer TTF and OS. In this retrospective analysis, front-line treatment regimen was a significant independent predictive factor for all three end points; chemoimmunotherapy was the superior treatment regimen. Considering front-line treatment regimen, other independent patient characteristics associated with CR included age and beta(2)-microglobulin (beta-2M). TTF was independently associated with age, beta-2M, percent lymphocytes in bone marrow, and treatment regimen. Improved OS was independently associated with younger age, lower beta-2M, and treatment regimen. Two weighted prognostic models or nomograms, one including and one excluding treatment regimen, were constructed using significant characteristics to predict 5- and 10-year survival probability and estimate median survival time. CONCLUSION: Identifying pretreatment patient characteristics associated with CR, TTF, and OS establishes a baseline to compare and incorporate new prognostic factors. Treatment had an impact on the significance of these factors. Prognostic models may help patients and clinicians in decision making as well as facilitate clinical research through design and analyses of clinical trials.
PURPOSE: Response to front-line treatment and subsequent clinical course for patients with chronic lymphocytic leukemia (CLL) are heterogeneous. Identifying pretreatment patient characteristics or prognostic factors associated with clinical outcomes is important for counseling patients, conducting clinical research, and evaluating trial results. PATIENTS AND METHODS: We evaluated the pretreatment characteristics of 595 previously untreated patients who had National Cancer Institute Working Group indications to initiate front-line therapy for predictors of complete response (CR), time to treatment failure (TTF), and overall survival (OS). Multivariable models were developed for all three end points. RESULTS:CR is an important treatment end point correlated with longer TTF and OS. In this retrospective analysis, front-line treatment regimen was a significant independent predictive factor for all three end points; chemoimmunotherapy was the superior treatment regimen. Considering front-line treatment regimen, other independent patient characteristics associated with CR included age and beta(2)-microglobulin (beta-2M). TTF was independently associated with age, beta-2M, percent lymphocytes in bone marrow, and treatment regimen. Improved OS was independently associated with younger age, lower beta-2M, and treatment regimen. Two weighted prognostic models or nomograms, one including and one excluding treatment regimen, were constructed using significant characteristics to predict 5- and 10-year survival probability and estimate median survival time. CONCLUSION: Identifying pretreatment patient characteristics associated with CR, TTF, and OS establishes a baseline to compare and incorporate new prognostic factors. Treatment had an impact on the significance of these factors. Prognostic models may help patients and clinicians in decision making as well as facilitate clinical research through design and analyses of clinical trials.
Authors: S M O'Brien; H M Kantarjian; J Cortes; M Beran; C A Koller; F J Giles; S Lerner; M Keating Journal: J Clin Oncol Date: 2001-03-01 Impact factor: 44.544
Authors: Michael J Keating; Susan O'Brien; Maher Albitar; Susan Lerner; William Plunkett; Francis Giles; Michael Andreeff; Jorge Cortes; Stefan Faderl; Deborah Thomas; Charles Koller; William Wierda; Michelle A Detry; Alice Lynn; Hagop Kantarjian Journal: J Clin Oncol Date: 2005-03-14 Impact factor: 44.544
Authors: Apostolia M Tsimberidou; Michael J Keating; Francis J Giles; William G Wierda; Alessandra Ferrajoli; Susan Lerner; Miloslav Beran; Michael Andreeff; Hagop M Kantarjian; Susan O'Brien Journal: Cancer Date: 2004-06-15 Impact factor: 6.860
Authors: B D Cheson; J M Bennett; K R Rai; M R Grever; N E Kay; C A Schiffer; M M Oken; M J Keating; D H Boldt; S J Kempin Journal: Am J Hematol Date: 1988-11 Impact factor: 10.047
Authors: John C Byrd; Bercedis L Peterson; Vicki A Morrison; Kathleen Park; Robert Jacobson; Eva Hoke; James W Vardiman; Kanti Rai; Charles A Schiffer; Richard A Larson Journal: Blood Date: 2002-07-05 Impact factor: 22.113
Authors: R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith Journal: Br J Cancer Date: 1977-01 Impact factor: 7.640
Authors: Paolo Strati; Alessandra Ferrajoli; Susan Lerner; Susan O'Brien; William Wierda; Michael J Keating; Stefan Faderl Journal: Leuk Lymphoma Date: 2013-07-29
Authors: Sameer A Parikh; Michael J Keating; Susan O'Brien; Xuemei Wang; Alessandra Ferrajoli; Stefan Faderl; Jan Burger; Charles Koller; Zeev Estrov; Xavier Badoux; Susan Lerner; William G Wierda Journal: Blood Date: 2011-07-12 Impact factor: 22.113
Authors: Alessandra Ferrajoli; Tait D Shanafelt; Cristina Ivan; Masayoshi Shimizu; Kari G Rabe; Nazila Nouraee; Mariko Ikuo; Asish K Ghosh; Susan Lerner; Laura Z Rassenti; Lianchun Xiao; Jianhua Hu; James M Reuben; Steliana Calin; M James You; John T Manning; William G Wierda; Zeev Estrov; Susan O'Brien; Thomas J Kipps; Michael J Keating; Neil E Kay; George A Calin Journal: Blood Date: 2013-07-02 Impact factor: 22.113
Authors: David Rodríguez; Gabriel Bretones; Javier R Arango; Víctor Valdespino; Elías Campo; Víctor Quesada; Carlos López-Otín Journal: Int J Hematol Date: 2015-01-29 Impact factor: 2.490
Authors: Kyle A Udd; Sean Bujarski; Eric Wirtschafter; Tanya M Spektor; Matthew Ghermezi; Laura Z Rassenti; Michael E David; Jason D Nosrati; Ashkon A Rahbari; James Wang; Suzie Vardanyan; Nika M Harutyunyan; Julia Linesch; Mingjie Li; Eric Sanchez; Haiming Chen; Thomas J Kipps; James R Berenson Journal: Target Oncol Date: 2019-10 Impact factor: 4.493
Authors: William G Wierda; Susan O'Brien; Xuemei Wang; Stefan Faderl; Alessandra Ferrajoli; Kim-Anh Do; Guillermo Garcia-Manero; Jorge Cortes; Deborah Thomas; Charles A Koller; Jan A Burger; Susan Lerner; Ellen Schlette; Lynne Abruzzo; Hagop M Kantarjian; Michael J Keating Journal: J Clin Oncol Date: 2011-10-03 Impact factor: 44.544